数据宝统计，截至09:54，三博脑科成交额42.41亿元，创上市以来新高。最新股价上涨10.67%，换手率 29.22%。上一交易日该股全天成交额为3.02亿元。（数据宝） （文章来源：证券时报网） ...

两融数据显示，该股最新（1月6日）两融余额为5.47亿元，其中，融资余额为5.45亿元，近10日减少 1265.59万元，环比下降2.27%。 公司发布的三季报数据显示，前三季度公司共实现营业收入12.73亿元，同比增长20.26%，实现净利润 8362.82万元，同比下降20.01%，基本每股收益为0.4100元，加权平均净资产收益率3.59%。（数据宝） （文章来源：证券时报网） 三博脑科股价创出历史新高，截至9:56，该股上涨13.00%，股价报95.98元，成交量4832.68万股，成交 金额43.63亿元，换手率30.03%，该股最新A股总市值达197.71亿元，该股A股流通市值154.48亿元。 证券时报·数据宝统计显示，三博脑科所属的医药生物行业，目前整体涨幅为0.69%，行业内，目前股价 上涨的有239只，涨停的有必贝特-U、嘉事堂等4只。股价下跌的有234只，跌幅居前的有锦好医疗、百 花医药、麦澜德等，跌幅分别为13.04%、9.97%、9.56%。 ...

新华财经北京1月7日电（丁晶、董道勇）新年伊始，脑机接口概念股集体"沸腾"，近20只个股连续两个交易日涨停。板块"开门红"缘 于市场对脑机接口巨大潜在需求、产业化进展提速及国家战略支持的叠加效应。 值得注意的是，新华财经数据显示，2026年1月5日该板块主力净流入29亿元，而6日主力资金开始净流出，规模近20亿元，但创新医 疗、爱朋医疗仍受主力资金追捧，继续保持净流入。分析认为，脑机接口行业正迎来"技术与商业化共振"的时刻，2026年脑机接口商 业化进程有望加速，并从医疗刚需向AI应用、机器人等多领域渗透。 长期来看，技术与合规双壁垒及业务联动长期看好头部企业形成技术与合规双壁垒，技术上具备核心专利、领先的研发能力，合规上 符合医疗行业严格的监管要求，如通过国家药监局的行业标准认证等。此外，关注传统业务与脑机接口业务具备联动性的企业，这类 企业可借助原有资源加速脑机接口业务的发展，同时脑机接口业务也能为传统业务带来新的增长极。 对于脑机接口加速"接入"现实，需要关注哪些细分领域？ 国信证券陈曦炳团队指出， 这是一个从0到1的增量市场。短期内，市场情绪受Neuralink量产预期和国内政策利好驱动，具备高爆发 ...

Core Insights - The brain-computer interface (BCI) sector is gaining significant attention, with multiple listed companies responding to the growing interest in this technology [1][4]. Company Responses - Companies such as Xiangyu Medical and Mailland have reported advancements in their BCI projects, with Xiangyu Medical aiming to enter over 1,000 top-tier hospitals in China and Mailland expecting to obtain its first BCI medical device registration certificate by Q1 2026 [5][6]. - Chengdu Huayi and Yingjixin have highlighted their roles in the BCI hardware segment, focusing on signal processing components essential for BCI performance [6][7]. Strategic Collaborations - Yijia is exploring the integration of BCI technology with embodied intelligence robotics, having signed a strategic cooperation agreement with Mailland to develop applications in smart healthcare [7]. - Yahui Long has announced a strategic partnership with Shenzhen Brain Chain Technology to enhance clinical applications and market expansion of BCI technologies [8]. Investment and Market Potential - Strong Brain Technology has recently secured approximately 2 billion yuan in funding, positioning itself as a major player in the BCI field, second only to Neuralink [8]. - The global BCI market is projected to reach approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, indicating substantial growth potential [9]. Industry Outlook - The BCI industry is expected to experience significant development opportunities driven by technological innovations, policy support, and capital investments, with promising prospects in healthcare and consumer markets [10].

Core Viewpoint - The A-share market has achieved significant milestones, with the Shanghai Composite Index closing at 4083.67 points, marking a ten-year high and a record 13 consecutive days of gains, indicating strong investor sentiment and a potential shift towards a balanced bull market in 2026 [1][2]. Market Performance - On January 6, all three major A-share indices rose, with the Shanghai Composite Index up by 1.50%, surpassing last year's high and reaching a ten-year peak [2]. - The market saw a surge in trading volume, reaching 2.83 trillion yuan, reflecting heightened investor enthusiasm [1]. - Notable sectors included brain-computer interfaces and commercial aerospace, with significant stock price increases and multiple stocks hitting their daily limit [2]. Fund Inflows - There is a strong expectation for capital inflows into the market, particularly from insurance and financing sectors, which are seen as core support for the current market rally [5]. - As of January 5, 2026, the financing balance reached a historical high of 2.54 trillion yuan, indicating robust market participation [5]. - Insurance funds have also seen substantial growth, with stock and fund allocations increasing by 1.49 trillion yuan since the beginning of the year [5]. Institutional Analysis - Analysts suggest that the current market dynamics are shifting from valuation-driven to profit-driven growth, with a more balanced market style expected [6][7]. - The ongoing economic recovery in China, supported by positive PMI data and industrial growth, provides a solid foundation for the stock market [7]. - Institutions recommend a balanced investment strategy, focusing on sectors like technology, consumer recovery, and high-dividend stocks [8][10]. Investment Strategies - Investment firms are advocating for a diversified approach, emphasizing sectors such as AI, semiconductor, and cyclical assets like metals and chemicals [8][10]. - There is a consensus on avoiding short-term speculation and focusing on long-term value in industries poised for growth [10]. - The recommendation includes a "barbell strategy," targeting both growth sectors and defensive assets to mitigate risks [8].

盘面上，脑机接口概念掀涨停潮，三博脑科、伟思医疗、爱朋医疗等多股涨停；保险、证券等金融 股走强，华林证券、华安证券涨停，新华保险涨超6%，中国太保涨超5%。此外，能源金属、小金属、 有色金属、航天航空、汽车服务、光伏、化纤、钛白粉概念等板块涨幅居前；美容护理、CPO概念等板 块跌幅居前。 编辑：何颖曦 中国经济周刊-经济网讯 A股三大指数今日集体收涨，沪指高开高走，再创十年新高。截至收盘， 上证综指报4083.67点，涨幅1.50%，成交额11757.69亿元；深证成指报14022.55点，涨幅1.40%，成交额 16307.39亿元；创业板指报3319.29点，涨幅0.75%，成交额7565.29亿元。 ...

Group 1 - The brain-computer interface sector opened high again, indicating strong investor interest and market momentum [1] - Companies such as Beiyikang and Meihao Medical reached new highs, reflecting positive performance and growth potential [1] - Innovative Medical, Nanjing Panda, and Yanshan Technology achieved three consecutive trading limit ups, showcasing significant market enthusiasm [1] Group 2 - Sanbo Brain Science and Daoshi Technology also experienced upward movement, indicating a broader trend of growth within the sector [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth and investment, highlighted by the recent 2 billion yuan financing of Qiangnao Technology, marking it as the second-largest financing in the field after Neuralink [3][4]. Group 1: Investment and Market Dynamics - Qiangnao Technology, part of the "Hangzhou Six Little Dragons," has completed approximately 2 billion yuan in financing, positioning itself as a major player in the BCI market [3][4]. - The BCI sector has become the hottest investment track in A-shares since the beginning of 2026, with multiple stocks like Innovation Medical, Aipeng Medical, and Xiangyu Medical achieving consecutive trading limit increases [3]. - The market is witnessing a surge in interest, with several BCI-related stocks announcing abnormal trading fluctuations, prompting warnings about investment risks [7]. Group 2: Company Developments - Qiangnao Technology, founded in 2015, focuses on non-invasive BCI technology and has received FDA and CE certifications, making it one of the largest investors in BCI R&D globally [4][5]. - The company has launched several products, including smart bionic limbs and brain-machine sleep aids, and has been recognized by Time magazine as one of the best inventions of the year [4]. - Qiangnao's investor lineup includes prominent institutions such as IDG and various strategic partners, indicating strong market confidence [4]. Group 3: Industry Trends and Future Outlook - The BCI industry is in a high-growth phase driven by policy support and technological breakthroughs, with expectations for large-scale production and automated surgical solutions from companies like Neuralink [6]. - The transition from clinical validation to commercial scalability is underway, suggesting that BCI technology is moving towards becoming widely accessible products rather than just experimental tools [6]. - Companies like Xiangyu Medical and Weisi Medical are focusing on non-invasive BCI technologies, although they currently have limited revenue contributions from these products [8][9].

Group 1: Stock Trading and Market Reactions - Multiple commercial aerospace and brain-computer interface stocks announced either trading suspensions or risk warnings due to significant price fluctuations [1] - Guosheng Technology's stock will be suspended from trading starting January 7, 2026, after experiencing a cumulative increase of 370.20% from October 31, 2025, to January 6, 2026 [1][2] - The stock price of Guosheng Technology has risen over 512% since October 13, 2025, closing at 21.30 yuan per share with a total market capitalization of 14 billion yuan [4] Group 2: Company Announcements and Business Developments - Guosheng Technology has diversified into the photovoltaic sector and is acquiring stakes in companies related to high-precision lithium battery components [3] - Jiamai Packaging announced a stock price increase of 230.48% from December 17, 2025, to January 6, 2026, prompting a trading suspension for risk assessment [6] - Jiamai Packaging's main business remains focused on food and beverage packaging, with no significant changes reported [6] Group 3: Risk Warnings and Market Conditions - Fenglong Co. issued a warning after seven consecutive trading days of price increases, indicating a potential suspension if prices continue to rise [8][10] - The stock price of Fenglong Co. has deviated significantly from its fundamental value, with a cumulative increase of 94.92% since December 25, 2025 [12] - North Star Navigation noted that its stock price has fluctuated significantly, with commercial aerospace being just one of its application scenarios [14] Group 4: Industry Trends and Future Outlook - Aerospace Hangyu expects that revenue from commercial aerospace will account for less than 15% of its total revenue in 2025, highlighting a disconnect between stock performance and actual business operations [16] - China Satellite reported a stock price increase of 156.07% since December 3, 2025, significantly outpacing industry and market indices, indicating potential overvaluation [24][25] - Xiangyu Medical is focusing on non-invasive brain-computer interface technology, with no large-scale sales achieved as of the end of 2025 [26]

Core Insights - The report emphasizes the strong growth potential in the electronic materials sector, driven by rapid advancements in downstream industries, continuous technological iterations, and the backdrop of domestic substitution [2][6][10] - The mechanical equipment industry is expected to benefit from structural technological growth, particularly in high-end manufacturing, with a focus on sectors like controlled nuclear fusion and humanoid robots [12][14][17] Electronic Materials Sector - The semiconductor materials market is projected to reach $67.5 billion in sales by 2024, with a year-on-year growth of 3.8%, and is expected to exceed $87 billion by 2029, reflecting a CAGR of 4.5% from 2024 to 2029 [7] - The PCB materials segment is experiencing a shift towards high-frequency and high-speed applications, with the global market for electronic resins and fabrics estimated at approximately $33.02 billion and $24.13 billion respectively in 2023 [8] - The OLED materials market is anticipated to grow significantly, with global sales expected to reach $2.44 billion in 2024 and $8.498 billion by 2031, representing a CAGR of 19.8% from 2025 to 2031 [9] Mechanical Equipment Sector - The controlled nuclear fusion sector is entering a phase of accelerated commercialization, with significant government support and technological breakthroughs expected to drive growth [13][17] - The liquid cooling market is set to expand rapidly due to increasing demands for AI computing power, with liquid cooling becoming essential for future AI servers and data centers [14][17] - The humanoid robot industry is transitioning into mass production, with several companies achieving order and delivery milestones, indicating a growing market for related components [15][17] Tourism and Social Services - Domestic tourism showed strong growth during the New Year holiday, with 142 million domestic trips taken, reflecting a 5.2% increase year-on-year, and total spending reaching approximately 84.79 billion yuan, up 6.3% [20][22] - The cross-border travel market is also experiencing significant growth, with a 28.6% increase in the number of people entering and exiting the country during the holiday period [23] Medical and Biological Sector - The brain-computer interface market is gaining traction, with companies like Neuralink planning large-scale production of devices by 2026, indicating a growing interest in this emerging field [26][28][30] - Domestic companies are making strides in the brain-computer interface space, with over 200 firms reported to be involved, highlighting the potential for significant advancements in this technology [29][30]